一项新的血液测试在大多数胶质母细胞瘤患者中检测到肿瘤细胞和囊泡，提供了一种有前途的非侵入性监测工具。 A new blood test detected tumor cells and vesicles in most glioblastoma patients, offering a promising non-invasive monitoring tool.

在环流肿瘤细胞第7次进步会议上提出的一项新的研究表明,ANGLE的Parsortix系统在60%新诊断的血浆瘤患者中检测到了循环肿瘤细胞(CTCs),在78%的阳性病例中发现了CTC群。 A new study presented at the 7th Advances in Circulating Tumour Cells meeting shows ANGLE’s Parsortix® system detected circulating tumour cells (CTCs) in 60% of newly diagnosed glioblastoma patients, with CTC clusters found in 78% of positive cases. 所有 CTC 都显示出间充质表型，这是标准方法经常遗漏的特征。 All CTCs showed a mesenchymal phenotype, a trait often missed by standard methods. 在73%的患者中检测到细胞外囊泡,支持液体活检的可能性. Extracellular vesicles were detected in 73% of patients, supporting liquid biopsy potential. 该技术能够同时将消毒剂和EV与单一的抽血方法隔离开来,为监测肿瘤生物学和治疗反应提供了最低限度的侵入性方法——特别宝贵,因为由于血脑屏障,在显微镜中很少发现CtDNA。 The technology enables simultaneous isolation of CTCs and EVs from a single blood draw, offering a minimally invasive way to monitor tumour biology and treatment response—especially valuable since ctDNA is rarely detected in glioma due to the blood-brain barrier. 该研究用于非诊断用途,需要进一步验证。 The research is for non-diagnostic use and requires further validation.